Nachrichten zur EyePoint Pharmaceuticals Inc. Aktie

Strategischer Auftakt in das Jahr 2026 EyePoint Pharmaceuticals (EYPT) hat das Jahr 2026 mit einer klaren Botschaft an die Kapitalmärkte…

EyePoint Pharmaceuticals files $200 million common stock offering prospectus…

EyePoint Pharmaceuticals stock maintains Outperform rating at Mizuho…

WATERTOWN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing…

EyePoint Pharmaceuticals stock sinks following clinical trial results…

EyePoint Pharmaceuticals Inc. (EYPT) hat sich auf Therapien zur Behandlung schwerer Netzhauterkrankungen spezialisiert. Im Fokus stehen zum Beispiel Lösungen für…

…

…

WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…

EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…

WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…

…

WATERTOWN, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…

WATERTOWN, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…

Cormorant Asset Management buys $10.49m in EyePoint Pharmaceuticals shares…

WATERTOWN, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing…

Earnings call: EyePoint Pharmaceuticals outlines growth and EYP-1901 progress…

…

EyePoint Pharmaceuticals appoints new Chief Medical Officer…